Observational studyMedicine2025
Neuroprotective effects of antenatal magnesium sulfate on neurodevelopmental outcomes in very low birth weight preterm infants: A 2-year follow-up study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antenatal magnesium sulfate (MgSO4) may provide neuroprotective benefits in preterm infants. This study examined the impact of antenatal MgSO4 on the neurodevelopmental outcomes of very low birth weight (VLBW) preterm infants at the corrected age of 2 years. This retrospective follow-up study included preterm infants with a birth weight ≤ 1500 g and gestational age ≤ 36 weeks who participated in a follow-up program. Antenatal MgSO4 was administered to treat maternal preeclampsia or for neuroprotection or tocolysis. Neurodevelopmental outcomes, including cerebral palsy (CP), neurodevelopmental impairment (NDI), and audiologic and visual assessments, were evaluated at a corrected age of 2 years. Infants exposed to MgSO4 were compared with unexposed controls. Among 328 VLBW infants (2007-2015), 133 were exposed to MgSO4, and 195 were not. Follow-up data were available for 93.3% of the infants. CP occurred in 6.0% of MgSO4 exposed infants versus 13.8% of controls (odds ratio: 0.39; 95% confidence interval: 0.18-0.91; P = .03). NDI was observed in 19.5% of exposed infants compared with 31.3% of controls (odds ratio: 0.53; 95% confidence interval: 0.32-0.90; P = .02). Multivariate logistic regression showed that low parental educational level (<college), birth weight (<1000 g), and periventricular leukomalacia were significantly associated with an increased rate of CP. Similarly, independent factors such as preeclampsia, low socioeconomic status, birth weight < 1000 g, male sex, and periventricular leukomalacia were significantly associated with an increased risk of NDI. Antenatal MgSO4 administration in pregnant women may have neuroprotective effects in VLBW preterm infants, reducing the risk of CP and NDI at the corrected age of 2 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.